

PROVIDER Update



CONTRACTUAL | JANUARY 10, 2024 | UPDATE 25-020 | 5 PAGES

New: 4th Quarter 2024 Injectable Medication HCPCS/DOFR Crosswalk

Use the updates for dates of service on and after March 18, 2025

The Pharmacy Advisory Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk. The Pharmacy Advisory Committee members include physicians and pharmacists.

The approved updates, effective March 18, 2025 are listed on pages 2-5 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net* and CalViva Health *Provider Participation Agreement (PPA)*.

The update includes:

- 23 new injectable medications to be added to the DOFR crosswalk.
- 11 updates and changes to current injectable medication procedure codes.
- 2 updated categories.
- 7 updates for new generic drugs.

Additional information

Relevant sections of the Plan's provider operations manuals will be revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library on the provider portal at provider.healthnetcalifornia.com > *Provider Library under Quick Links*, or go directly to providerlibrary.healthnetcalifornia.com.

If you have questions regarding the information contained in this update, contact CalViva Health at 888-893-1569.

THIS UPDATE APPLIES TO:

- Participating Physician Groups

PROVIDER SERVICES

CalViva Health Medi-Cal
(including ECM and CS providers) –
888-893-1569

PROVIDER PORTAL

provider.healthnetcalifornia.com

Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Aucatzyl®	Obecabtagene autoleucel suspension for intravenous infusion	Therapeutic injection	Chemotherapy ¹
TBD	Audenz™	Influenza A (H5N1) tiss-cult subunit adjuvanted IM emulsion	Therapeutic injection	Immunization
J3490	Bridion®	Sugammadex injection for intravenous use. Initial United States approval 2015	Therapeutic injection	
C9399	Cytelzo®	Adalimumab-adbm; Low Conc., interchangeable	Self-injectable	
J3590	Ebglyss™	Lebrikizumab-lbkz subcutaneous solution auto-injection 250 mg/2ml	Self-injectable	
J3490	Enzeevu™	Aflibercept-abzv	Therapeutic injection	
J9301	Gazyva®	Obinutuzumab injection, for intravenous use	Therapeutic injection	Chemotherapy ¹
J9248	Hepzato kit™	Melphalan for intra-arterial solution 59 mg	Therapeutic injection	Chemotherapy ¹
J3590	Hympavzi™	Marstacimab-hncq injection, for subcutaneous use	Self-injectable	Blood/blood products for hemophilia
J9999	Lymphir™	Denileukin diftitox-cxdl	Therapeutic injection	Chemotherapy ¹
J3590	Nemluvio®	Nemolizumab-ilto 30 mg auto-injector	Self-injectable	
J3590	Niktimvo™	Axatilimab-csfr	Therapeutic injection	
J3590	Ocrevus zunovo™	Ocrelizumab hyaluronidase-ocsq	Therapeutic injection	
J3590	Pavblu™	Aflibercept-ayyh intravitreal injection 2 mg/0.05 mL	Therapeutic injection	
J3590	Piasky®	Crovalimab-akkz injection, for intravenous or subcutaneous	Therapeutic injection	

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

New drugs, continued

HCPCS	Drug name	Generic name	Primary category	Secondary category
J9999	Tecelra®	Afamitresgene autoleucel IV suspension 10,000,000,000 cells	Therapeutic injection	Chemotherapy ¹
J9999	Tecentriq hybreza™	Atezolizumab hyaluronidase-tqjs injection 1875-30000 mg-unit/15 mL	Therapeutic injection	Chemotherapy ¹
J1628	Tremfya® IV	Guselkumab injection for intravenous use	Therapeutic injection	
Q5135	Tyenne®	Tocilizumab-aazg injection for intravenous or subcutaneous use	Therapeutic injection	Home health/ Infusion ²
J3490	Yorvipath®	Palopegteriparatide injection for subcutaneous use	Self-injectable	
J9999	Vyloy®	Zolbetuximab-clzb for IV solution 100 mg	Therapeutic injection	Chemotherapy ¹
J3590	Yuflyma®	Adalimumab-aaty; high concentration	Self-injectable	
J3490	Zurnaj™	Nalmefene injection, for intramuscular or subcutaneous use	Self-injectable	

Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
C9167	Adzynma®	Injection, ADAMTS13, recombinant-krhn, 10 international units (IU)	Code deletion
C9172	Beqvez™	Fidanacogene elaparovec-dzkt injection, for intravenous infusion	Replaces J3590
C9166	Cosentyx®	Injection, secukinumab, intravenous, 1 mg	Code deletion
J1170	Hydromorphone	Injection, hydromorphone, up to 4 mg	Code deletion
J2001	Lidocaine	Injection, lidocaine hydrochloride for intravenous infusion, 10 mg	Code deletion
J9371	Marqibo®	Injection, vincristine sulfate liposome, 1 mg	Code deletion

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

²When administered by a nurse in a home setting.

Updates/changes to injectable medication procedure codes or medications, *continued*

HCPCS	Drug name	Generic name	Comment
J2470	Pantoprazole	Injection, pantoprazole sodium, 40 mg	Code deletion – replaces S0164
J2470	Pantoprazole	Injection, pantoprazole sodium, per vial	Code deletion – replaces C9113
J9258	Paclitaxel protein-bound particles	Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to J9264, 1 mg	Code deletion
J2780	Ranitidine	Injection, ranitidine hydrochloride, 25 mg	Code deletion
J9329	Tevimbra®	Tislelizumab-jsgr injection, for intravenous use	Replaces J3590

Category changes

The following medications have been approved to correct the secondary category listed below.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J0485	Nulojix®	Belatacept, 1 mg injection	Therapeutic injection	Transplant
J1932	Lanreotide 1 mg (Cipla)	Lanreotide acetate, 1 mg	Therapeutic injection	Chemotherapy adjunctive ¹

New generic injectable medications

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J0893	Decitabine	Injection, decitabine (sun pharma), not therapeutically equivalent to J0894	Therapeutic injection	Chemotherapy ¹
J9393	Fulvestrant	Injection, fulvestrant (teva), not therapeutically equivalent to J9395, 25 mg	Therapeutic injection	Chemotherapy ¹
J0651	Levothyroxine	Injection, levothyroxine sodium (fresenius kabi), not therapeutically equivalent to J0650, 10 mcg	Therapeutic injection	

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

New generic injectable medications, *continued*

HCPCS	Drug name	Generic name	Primary category	Secondary category
J0652	Levothyroxine	Injection, levothyroxine sodium (Hikma), not therapeutically equivalent to J0650, 10 mcg	Therapeutic injection	
J0650	Levothyroxine	Levothyroxine sodium not otherwise specified injection, 10 mcg	Therapeutic injection	
J9296	Pemetrexed	Injection, pemetrexed (Accord), not therapeutically equivalent to J9305, 10 mg	Therapeutic injection	Chemotherapy ¹
J9314	Pemetrexed	Injection, pemetrexed teva, not therapeutically equivalent to J9305, 10 mg	Therapeutic injection	Chemotherapy ¹

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.